Lisa Kuhns, PhD, MD

News
Systematic Review Highlights Key Symptoms Impacting Quality of Life in Patients With Parkinson Disease and Care Partners
11/15/2024
People with Parkinson disease (PD) and their care partners (CPs) face significant challenges affecting their health-related quality of life (HRQOL), with different PD symptoms impacting them as the disease progresses.
People with Parkinson disease (PD) and their care partners (CPs) face significant challenges affecting their health-related quality of life (HRQOL), with different PD symptoms impacting them as the disease progresses.
People with Parkinson disease...
11/15/2024
Annals of Long-Term Care
News
Women Face Higher Mortality Risk from Postoperative Atrial Fibriliation Despite Lower Incidence Postsurgery
11/14/2024
While men are more likely to develop postoperative atrial fibrillation (poAF) after open-heart surgery, women with poAF face a higher risk of long-term mortality compared to men.
While men are more likely to develop postoperative atrial fibrillation (poAF) after open-heart surgery, women with poAF face a higher risk of long-term mortality compared to men.
While men are more likely to...
11/14/2024
Annals of Long-Term Care
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Cybersecurity as a Strategic Imperative to Protect Patient Safety in Health Care
11/07/2024
Cybersecurity is essential for protecting patient safety, requiring health care leaders to prioritize it as a strategic issue and integrate it into risk management to mitigate evolving cyber threats.
Cybersecurity is essential for protecting patient safety, requiring health care leaders to prioritize it as a strategic issue and integrate it into risk management to mitigate evolving cyber threats.
Cybersecurity is essential for...
11/07/2024
Integrated Healthcare Executive
News
Study Reveals Key Predictors of Dementia Risk in Patients With Parkinson Disease
11/01/2024
Age, sex, and education are key dementia risks in Parkinson disease.
Age, sex, and education are key dementia risks in Parkinson disease.
Age, sex, and education are key...
11/01/2024
Annals of Long-Term Care
News
Above-label Use is Most Frequent Among Patients With Psoriasis Receiving Etanercept and Ixekizumab, Resulting in Higher Costs but Few Safety Concerns
06/24/2021
Patients with psoriasis receiving etanercept, ixekizumab, adalimumab, and secukinumab had more frequent above-label use of biologics for treatment, which resulted in additional costs but few safety concerns.
Patients with psoriasis receiving etanercept, ixekizumab, adalimumab, and secukinumab had more frequent above-label use of biologics for treatment, which resulted in additional costs but few safety concerns.
Patients with psoriasis...
06/24/2021
The Dermatologist
PsA joint pain
Obesity Negatively Impacts QOL, Psychological Status, and Disease Activity in Patients With PsA
09/24/2021
Patients with psoriatic arthritis (PsA) and obesity experience a lower quality of life (QOL), higher disease activity, and higher risk of anxiety and depression. Researchers aimed to evaluate the effect of obesity on QOL, psychological...
Patients with psoriatic arthritis (PsA) and obesity experience a lower quality of life (QOL), higher disease activity, and higher risk of anxiety and depression. Researchers aimed to evaluate the effect of obesity on QOL, psychological...
Patients with psoriatic...
09/24/2021
The Dermatologist
News
Risankizumab Showed Efficacious and Favorable Safety Profile for Psoriatic Arthritis
10/25/2022
Researchers conducted population pharmacokinetic and exposure-response analyses on risankizumab in patients with active PsA.
Researchers conducted population pharmacokinetic and exposure-response analyses on risankizumab in patients with active PsA.
Researchers conducted population...
10/25/2022
The Dermatologist

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use